4 stories mentioning STROUpdated 27d ago
Every FINWIRES story that references STRO, newest first.
Sutro Biopharma (STRO) has an average rating of buy and mean price target of $47.42, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
(Updates with the company's stock move in the headline and in the first paragraph, cash runway estimate in the sixth paragraph, Wedbush upgrade in the seventh paragraph.)Sutro Biopharma (STRO) shares were up 1.9% in Friday trading after the company reported a narrower Q1 loss late Thursday.The company posted a quarterly loss of $2.94 per diluted share, narrowing from a loss of $9.08 a year earlier.Analysts surveyed by FactSet expected a loss of $2.74.Revenue for the three months ended March 31 was $14.5 million, down from $17.4 million a year earlier.Analysts polled by FactSet expected $8.9 million.Sutro Biopharma said that its cash runway is now expected into at least Q2 of 2028, excluding additional anticipated milestones from its existing collaborations.Wedbush upgraded its rating on the company's stock to outperform from neutral and raised its price target to $60 from $22.Price: $39.31, Change: $+0.89, Percent Change: +2.32%
Sutro Biopharma (STRO) has an average rating of buy and mean price target of $35.73, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Sutro Biopharma (STRO) has an average rating of buy and mean price target of $33.90 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
